Aurinia Pharmaceuticals Inc (AUPH) - What Are Brokerages Saying About This Stock?

Key Points

• Aurinia Pharmaceuticals has a “Moderate Buy” consensus rating among seven analysts, with three buys, three holds and one strong buy. The average 12-month price target is $17.75.
• Recent analyst actions were mixed but generally positive: RBC and TD Cowen raised their price targets to $16 and $18, respectively, while Bloom Burton and Weiss Ratings upgraded the stock; Zacks Research downgraded it to a hold.
• Aurinia reported quarterly earnings of $0.28 per share, beating estimates of $0.24, although revenue of $58.57 million fell short of the $80.45 million consensus estimate. Institutional investors own 36.83% of the company.

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP have been given a consensus rating of "Moderate Buy" by the seven brokerages that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $17.75.

A number of research firms recently issued reports on AUPH. Royal Bank Of Canada raised their price target on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a "sector perform" rating in a research note on Friday, August 7th. Bloom Burton upgraded Aurinia Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 20th. Weiss Ratings raised Aurinia Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 26th. TD Cowen raised their target price on shares of Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Zacks Research lowered shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 21st.

Institutional Trading of Aurinia Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Nykredit A S acquired a new position in Aurinia Pharmaceuticals in the second quarter valued at $35,000. Global Retirement Partners LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at about $41,000. Quantbot Technologies LP acquired a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth about $45,000. Frazier Financial Advisors LLC boosted its stake in shares of Aurinia Pharmaceuticals by 411.9% during the first quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company's stock worth $51,000 after buying an additional 2,793 shares during the period. Finally, Allworth Financial LP acquired a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth about $56,000. Institutional investors and hedge funds own 36.83% of the company's stock.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH stock opened at $17.33 on Friday. The stock's 50-day moving average is $16.35 and its two-hundred day moving average is $16.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.97 and a current ratio of 5.42. Aurinia Pharmaceuticals has a 1 year low of $11.48 and a 1 year high of $19.25. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of 7.57 and a beta of 1.60.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.04. The business had revenue of $58.57 million during the quarter, compared to the consensus estimate of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. Analysts predict that Aurinia Pharmaceuticals will post 0.90 earnings per share for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.